Castle Biosciences' DecisionDx-Melanoma predicts five-year recurrence more accurately than AJCC staging in study
CSTL•A study of 1,726 patients found Castle Biosciences' DecisionDx-Melanoma recurrence-risk algorithm predicted five-year recurrence more accurately than standard melanoma staging; a separate study of 750 patients found it identified higher mortality risk in some thin melanomas considered low risk.
1. Study findings
Castle Biosciences said findings from two studies of DecisionDx-Melanoma will be presented at SDPA on Nov. 11-15, 2026, and Dermato-Onco2026 on Nov. 12-13. One study of 1,726 patients found the algorithm predicted five-year recurrence more accurately than standard melanoma staging, while another study of 750 patients found it identified higher mortality risk in some thin melanomas traditionally considered low risk.
